Press

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Oct 4 • 3 min read

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of psilocybin-based therapeutics, today provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics, Inc. Following the completion of necessary due diligence and other pre-closing activities specified in the conditional binding term sheet that was announced on September 9, 2024,…

Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

Oct 4 • 3 min read

Toronto, Ontario–(Newsfile Corp. – October 4, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (“AUD”), today announced the selection of Eurofins Discovery to conduct…

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Oct 2 • 1 min read

Dallas, Texas–(Newsfile Corp. – October 2, 2024) – Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Click image above to view full announcement. About Stonegate Stonegate Capital Partners is a leading capital…

Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™

Oct 2 • 4 min read

Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma (“Alera or Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent number 12,102,616 titled “Psilocin Mucate”. As…

PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA

Oct 2 • 3 min read

TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Harvard’s Maclean…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441